桑白皮-甘草2:1配比通过抑制花生四烯酸代谢通路缓解慢性阻塞性肺疾病
该研究结合处方数据挖掘与COPD大鼠模型,确定桑白皮(MRB)与甘草的核心配伍,并发现2:1组疗效更优。网络药理学与代谢组学联合分析提示其通过调控花生四烯酸(AA)代谢、降低ALOX5、LTA4H及LTB4水平减轻炎症与黏液分泌。
要点
- 桑白皮-甘草为治疗COPD的核心药对,2:1配比疗效更佳
- 该药对可改善COPD大鼠呼吸功能与肺组织病理
- 机制可能与抑制AA代谢通路及LTB4生成有关
核心结论
- 桑白皮-甘草2:1配比能更有效缓解COPD大鼠炎症与黏液分泌,可能通过调控花生四烯酸代谢通路实现。
研究设计与样本
- 研究先挖掘临床文献与中医处方数据库分析用药规律,再建立烟熏加气道脂多糖(LPS)滴入的COPD大鼠模型评估配伍剂量与疗效。
- 随后采用网络药理学预测靶点,液相色谱-质谱进行血浆代谢组学分析,并联用MetaboAnalyst与GEO数据集交集基因分析,最后以ELISA验证关键代谢酶与基因。
主要发现
- 桑白皮-甘草可改善COPD大鼠呼吸功能与肺组织病理形态,并降低IL-1β、TNF-α和MUC5AC蛋白表达。
- 不同剂量间存在显著差异,其中桑白皮-甘草2:1组对COPD大鼠的治疗效果更好。
- 网络药理学显示桑白皮-甘草中80个化合物调控112个靶点,涉及谷胱甘肽代谢与花生四烯酸(AA)代谢等通路。
- 代谢组学显示桑白皮-甘草调控13个差异代谢物,涉及AA代谢与精氨酸生物合成等通路。
- 联合分析确定白三烯B4(LTB4)为关键差异代谢物,AA代谢为关键代谢通路,ALOX5与LTA4H为关键基因;ELISA验证显示桑白皮-甘草降低COPD大鼠血浆ALOX5、LTA4H及LTB4水平。
关键数值与推荐
- 桑白皮-甘草为治疗COPD的核心中药配伍,2:1配比组疗效优于其他剂量组。
- 网络药理学预测80个化合物作用于112个靶点,涉及谷胱甘肽代谢和AA代谢等通路。
- 代谢组学识别13个差异代谢物,涉及AA代谢和精氨酸生物合成等通路。
临床怎么用
- 临床可参考桑白皮-甘草2:1的配伍比例用于COPD患者,但需结合辨证与个体化处方。
- 该药对可能通过抑制AA代谢通路及LTB4生成发挥抗炎与减少黏液分泌作用,可作为机制解释参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The compatibility of natural herbs has been gradually recognized for its efficacy and safety in treating lung diseases. Morus alba L. root bark (MRB) and Glycyrrhiza uralensis (Licorice) are traditional Chinese medicines (TCM) with a long history of use. They are often combined to treat chronic obstructive pulmonary disease (COPD). However, the optimal ratio for combining MRB and licorice and the underlying mechanism of this combination in the treatment of COPD need to be further clarified. AIM OF THE STUDY: To determine the optimal compatibility dose relationship of MRB-Licorice in the current prescriptions and investigate its potential mechanism in the treatment of COPD. MATERIALS AND METHODS: We collected the published clinical intervention literature and TCM prescription databases related to COPD treatment. R software (3.3.1) was used to analyze the frequency of medicine use, properties, combination methods, and to explore the core drug combinations in COPD treatment. A rat model of COPD was established through smoke inhalation and airway Lipopolysaccharide (LPS) instillation to evaluate the compatible dosage and effectiveness of the MRB-Licorice combination. Respiratory function, pathological morphology of lung tissue, and the expression of inflammatory factor were observed in rats to assess the effect of core combination of drugs in treating COPD. Subsequently, network pharmacology was constructed to predict the targets of core drugs for COPD treatment. Liquid chromatography-mass spectrometry was used to study plasma metabolomics and explore the regulatory effect of the core Chinese medicines on metabolites. A joint analysis of predicted targets and differential metabolites was conducted using MetaboAnalyst to identify critical metabolites and metabolic pathways. Additionally, intersection genes from human and rat Gene Expression Omnibus (GEO) datasets were analyzed. Finally, ELISA validation was conducted on key metabolic enzymes and genes. RESULTS: MRB-Licorice exhibit the core Chinese herbal medicine compatibility for COPD treatment. MRB-Licorice improved respiratory function and lung histopathology, and reduced the expression of IL-1β, TNF-α, and MUC5AC proteins in COPD rats. Furthermore, significant differences were observed across different dosages, with the MRB-Licorice 2:1 group showing better therapeutic effects on COPD rats. In network pharmacology, 80 compounds from MRB-Licorice modulated 112 targets and acted by regulating pathways like glutathione metabolism and arachidonic acid (AA) metabolism. Metabolomics analysis showed that MRB-Licorice regulated 13 differential metabolites, and accordingly, regulated pathways, such as AA metabolism and arginine biosynthesis. Co-analysis of the 112 targets and 13 metabolites revealed that leukotriene B4 (LTB4) was the key differential metabolite, and AA metabolism was the key metabolic pathway. Arachidonic acid 5-lipoxygenase (ALOX5) and leukotriene A4 hydrolase (LTA4H) were identified as key genes through a joint analysis of the intersection genes from human and rat GEO datasets, key metabolic pathway genes, and core drug genes. Based on these results, we further verified MRB-Licorice reduced the levels of ALOX5, LTA4H, and LTB4 in the plasma of COPD rats. CONCLUSION: The MRB-Licorice 2:1 treatment was more effective in alleviating inflammation and mucus secretion in COPD rats, probably via the regulation of AA metabolism.
引用
- Du H, Xu S, Ke H, et al. Morus alba L.-Glycyrrhiza uralensis alleviate chronic obstructive pulmonary disease by inhibiting the arachidonic acid metabolism pathway. J Ethnopharmacol. 2025. PMID: 40324701. doi:10.1016/j.jep.2025.119904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。